Drug Trial Radar · NCT07222748
A Study of TLC590 for Postsurgical Pain Following Bunionectomy
Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
304
Actual
Start
Nov 17, 2025
Primary completion
Jun 12, 2026
Study completion Jul 2026
Sponsor
- Lead sponsor
- TLC Biopharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, double-blind, comparator- and placebo-controlled study to evaluate analgesic efficacy and safety of TLC590 via local infiltration in adult subjects following bunionectomy.
Conditions
- Postoperative Pain
Interventions
TLC590Drug
TLC590 (Ropivacaine Extended-Release Injectable Suspension)
Liposomal BupivacaineDrug
Bupivacaine Liposome Injectable Suspension
Saline PlaceboDrug
Normal Saline 0.9%
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours Postsurgery (AUC0-72), Compared with Saline Placebo.Time frame: 72 hours
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Clinical Pharmacology of Miami
Miami, Florida
First Surgical Hospital
Bellaire, Texas
Memorial Hermann Village
Houston, Texas
Endeavor Clinical Trials
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.